BRCA2/TP53/PTEN 缺失型转移性子宫平滑肌肉瘤对奥拉帕利的快速反应：一例报告。
Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.
机构信息
Department of Oncology and Hematology, Kaiser Permanente, Santa Clara, CA.
Division of Research, Kaiser Permanente, Oakland, CA.
出版信息
Perm J. 2021 May;25. doi: 10.7812/TPP/20.251.
Abstract
Patients with metastatic uterine leiomyosarcoma (uLMS) have poor prognosis due to limited treatment options, especially when disease progresses on doxorubicin and gemcitabine-docetaxel regimens. Here we report a patient whose metastatic uLMS contains a BRCA2 deep deletion as well as TP53 and PTEN deep deletion. The patient responded rapidly to olaparib, a poly (ADP-ribose) polymerase inhibitor, after progressing on gemcitabine-docetaxel, doxorubicin, and temozolomide regimens. This case report shall be helpful to the treatment of other patients with metastatic uLMS that harbors a BRCA2 mutation or deletion.
摘要
患有转移性子宫平滑肌肉瘤（uLMS）的患者由于治疗选择有限，预后较差，尤其是在多柔比星和吉西他滨-多西紫杉醇方案治疗进展后。在这里，我们报告了一名患者，其转移性 uLMS 存在 BRCA2 深度缺失以及 TP53 和 PTEN 深度缺失。该患者在吉西他滨-多西紫杉醇、多柔比星和替莫唑胺方案进展后，对聚（ADP-核糖）聚合酶抑制剂奥拉帕利迅速产生反应。本病例报告将有助于治疗其他携带 BRCA2 突变或缺失的转移性 uLMS 患者。
相似文献
1
Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.
Perm J. 2021 May;25. doi: 10.7812/TPP/20.251.
2
Targeting homologous recombination deficiency in uterine leiomyosarcoma.
J Exp Clin Cancer Res. 2023 May 4;42(1):112. doi: 10.1186/s13046-023-02687-0.
3
Functional Loss Defines a Targetable Subset in Leiomyosarcoma.
Oncologist. 2019 Jul;24(7):973-979. doi: 10.1634/theoncologist.2018-0448. Epub 2018 Dec 12.
4
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Oncologist. 2024 Jul 5;29(7):560-565. doi: 10.1093/oncolo/oyae082.
5
Integrated mutational landscape analysis of uterine leiomyosarcomas.
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15). doi: 10.1073/pnas.2025182118.
6
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
Clin Cancer Res. 2020 Jul 15;26(14):3881-3888. doi: 10.1158/1078-0432.CCR-19-3959. Epub 2020 Apr 16.
7
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
J Clin Oncol. 2023 Sep 1;41(25):4154-4163. doi: 10.1200/JCO.23.00402. Epub 2023 Jul 19.
8
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
BMC Med Genet. 2018 Oct 17;19(1):185. doi: 10.1186/s12881-018-0703-9.
9
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common Alteration.
Oncologist. 2017 Apr;22(4):416-421. doi: 10.1634/theoncologist.2016-0310. Epub 2017 Mar 10.
10
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
Nat Rev Clin Oncol. 2011 May;8(5):302-6. doi: 10.1038/nrclinonc.2011.42. Epub 2011 Apr 5.
引用本文的文献
1
Next-Generation Sequencing-Guided Treatment of BRCA2-Mutant Metastatic Uterine Leiomyosarcoma With Poly(ADP-ribose) Polymerase Inhibitor Therapy.
JCO Precis Oncol. 2024 Dec;8:e2400401. doi: 10.1200/PO-24-00401. Epub 2024 Dec 12.
2
PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma.
BJC Rep. 2024 Jan 30;2(1):9. doi: 10.1038/s44276-023-00029-3.
3
Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy.
Cells. 2024 Jun 26;13(13):1106. doi: 10.3390/cells13131106.
4
PARP inhibitors in non-ovarian gynecologic cancers.
Ther Adv Med Oncol. 2024 Jun 12;16:17588359241255174. doi: 10.1177/17588359241255174. eCollection 2024.
5
Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years' clinical experience from a tertiary care center in Pakistan.
BMC Cancer. 2023 Jun 5;23(1):510. doi: 10.1186/s12885-023-11000-3.
6
Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic mutation.
Gynecol Oncol Rep. 2022 Jul 14;42:101044. doi: 10.1016/j.gore.2022.101044. eCollection 2022 Aug.
7
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
J Gynecol Oncol. 2022 Jul;33(4):e55. doi: 10.3802/jgo.2022.33.e55. Epub 2022 May 3.
8
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.
NPJ Precis Oncol. 2022 Apr 25;6(1):29. doi: 10.1038/s41698-022-00271-x.
本文引用的文献
1
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
2
Functional Loss Defines a Targetable Subset in Leiomyosarcoma.
Oncologist. 2019 Jul;24(7):973-979. doi: 10.1634/theoncologist.2018-0448. Epub 2018 Dec 12.
3
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
4
GeDDiS: insight into frontline therapy in soft tissue sarcoma.
Lancet Oncol. 2017 Oct;18(10):1297-1299. doi: 10.1016/S1470-2045(17)30672-1. Epub 2017 Sep 4.
5
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14.
6
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
J Clin Oncol. 2012 Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18.
7
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
EMBO Mol Med. 2012 Jun;4(6):515-27. doi: 10.1002/emmm.201200229. Epub 2012 Mar 13.
8
The DNA damage response and cancer therapy.
Nature. 2012 Jan 18;481(7381):287-94. doi: 10.1038/nature10760.
9
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Cell Cycle. 2011 Apr 15;10(8):1192-9. doi: 10.4161/cc.10.8.15273.
10
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
Nat Rev Clin Oncol. 2011 May;8(5):302-6. doi: 10.1038/nrclinonc.2011.42. Epub 2011 Apr 5.
Zotero 插件